CD8A and neoplasm: In parallel to the changed ratio of CD8+/CD4+ T cells, FVS also revealed an increased number of tumor death in ccRCC-03_PDO and ccRCC-06_PDO after toripalimab treatment, exhibiting anti PD-1 dependent tumor killing.